BioSpace News Archive

The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.

BMS’s ongoing Phase III randomized, double-blind, multi-center study – named CheckMate-274 – compares Opdivo against a placebo in 709 participants deemed to be at a high risk of recurrence after radical surgery.

Starting with just $11 million seed in 2015, investors have proven their faith in InvestiBio with their increasing financial support.

Barry Bloom, Ph.D., research professor of public health and former dean at the Harvard T.H. Chan School of Public Health, participated in an online forum titled “The Coronavirus Pandemic: Global Race for a Vaccine” held September 15.

A team of more than 60 scientists and bioethicists have signed a letter urging Pfizer to wait until late November before the company seeks FDA authorization of its COVID-19 vaccine candidate in an effort to ensure rigorous safety standards have been met.

The new approval makes it the first FDA-approved therapy in over a decade to treat HES and the third indication for the therapy overall.

XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, now has $318.8 million more to bring drug development into the future.

Pennsylvania-based Inovio said the regulatory agency has additional questions about the Phase II/III trial regarding the vaccine candidate itself, known as INO-4800, as well as the company’s Cellectra 2000 delivery device.

On Face the Nation, Gottlieb said hospitalization rates in the United States for COVID-19 had been in a state of decline, but those numbers are now rising, which goes hand in hand with an increase in infection rates.

- $82.9 Million in Cash and Cash Equivalents at June 30, 2020 - Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® in July 2020 Resulted in Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 - Phase 2 Study Data of PL9643 for the Treatment of Dry Eye Disease Expected in Fourth Calendar Quarter of 2020 - Teleconference and Webcast to be held on September 28, 2020